4.6 Article

Cytotoxic Dendritic Cells Generated from Cancer Patients

Journal

JOURNAL OF IMMUNOLOGY
Volume 187, Issue 5, Pages 2775-2782

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1004146

Keywords

-

Categories

Funding

  1. La Ligue contre le Cancer
  2. Conseil Regional de Bourgogne
  3. University Hospital of Dijon
  4. National Institutes of Health [R01 CA104926]
  5. Arizona Cancer Center [CA023074]
  6. Tee Up for Tots and People Acting Now Discover Answers

Ask authors/readers for more resources

Known for years as professional APCs, dendritic cells (DCs) are also endowed with tumoricidal activity. This dual role of DC as killers and messengers may have important implications for tumor immunotherapy. However, the tumoricidal activity of DCs has mainly been investigated in animal models. Cancer cells inhibit antitumor immune responses using numerous mechanisms, including the induction of immunosuppressive/tolerogenic DCs that have lost their ability to present Ags in an immunogenic manner. In this study, we evaluated the possibility of generating tumor killer DCs from patients with advanced-stage cancers. We demonstrate that human monocyte-derived DCs are endowed with significant cytotoxic activity against tumor cells following activation with LPS. The mechanism of DC-mediated tumor cell killing primarily involves peroxynitrites. This observed cytotoxic activity is restricted to immature DCs. Additionally, after killing, these cytotoxic DCs are able to activate tumor Ag-specific T cells. These observations may open important new perspectives for the use of autologous cytotoxic DCs in cancer immunotherapy strategies. The Journal of Immunology, 2011, 187: 2775-2782.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available